Education
About Us
Working with TipRanks
Follow Us
Cel-sci (CVM)
:CVM
CVM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.98 - $66.57
Previous Close$0.36
Volume1.47M
Average Volume (3M)328.65K
Market Cap
$11.76M
Enterprise Value$125.96M
Total Cash (Recent Filing)$4.61M
Total Debt (Recent Filing)$11.09M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding5,135,021
10 Day Avg. Volume331,813
30 Day Avg. Volume328,646
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio-7.05
Enterprise Value/Market Cap10.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.50
Enterprise Value/Ebitda-1.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cel-Sci News
Ownership Overview
31.97% Insiders
9.52% Mutual Funds
1.78% Other Institutional Investors
54.88% Public Companies and Individual Investors
CVM FAQ
What was Cel-sci’s price range in the past 12 months?
Cel-sci lowest stock price was $1.98 and its highest was $66.57 in the past 12 months.
What is Cel-sci’s market cap?
Cel-sci’s market cap is $11.76M.
When is Cel-sci’s upcoming earnings report date?
Cel-sci’s upcoming earnings report date is Aug 18, 2025 which is in 59 days.
How were Cel-sci’s earnings last quarter?
Cel-sci released its earnings results on May 15, 2025. The company reported -$2.4 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.4.
Is Cel-sci overvalued?
According to Wall Street analysts Cel-sci’s price is currently Overvalued.
Does Cel-sci pay dividends?
Cel-sci does not currently pay dividends.
What is Cel-sci’s EPS estimate?
Cel-sci’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-sci have?
Cel-sci has 5,135,021 shares outstanding.
What happened to Cel-sci’s price movement after its last earnings report?
Cel-sci reported an EPS of -$2.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.144%.
Which hedge fund is a major shareholder of Cel-sci?
Currently, no hedge funds are holding shares in CVM
Cel-Sci Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.12%
12-Months-Change
Fundamentals
Return on Equity
-238.64%
Trailing 12-Months
Asset Growth
-27.43%
Trailing 12-Months
Company Description
Cel-sci
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.